SCYNEXIS, Inc. (SCYX) Stock Ticker
Market factors today
Unlock the full SCYX picture
About SCYNEXIS, Inc.
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
SCYX stock facts
| Ticker symbol | SCYX |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical - Pharmaceuticals |
| Market cap | $27.6M |
| CEO | David Angulo |
| Employees | 18 |
| Headquarters | Jersey City, NJ, US |
| IPO date | 2014-05-02 |
| Website | www.scynexis.com |
What you can see for SCYX on Tickr
Live SCYX price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the SCYX report.
Rankings
FAQ
What is the ticker symbol for SCYNEXIS, Inc.?
The ticker symbol for SCYNEXIS, Inc. is SCYX, listed on the NASDAQ.
What is SCYX?
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques…